- Lisa Wyman brings more than 20 years of
leadership and functional experience to new role of Chief Technical
and Quality Officer on the Executive Team at Scholar Rock
- Ted Myles, Chief Operating Officer &
Chief Financial Officer, will continue to operate through
transition phase to a new organizational structure
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical
company focused on advancing innovative treatments for spinal
muscular atrophy (SMA), cardiometabolic disorders, and other
serious diseases where protein growth factors play a fundamental
role, announced today that Lisa Wyman has been appointed to the new
role of Chief Technical and Quality Officer (CTQO) to support the
Company’s ongoing growth and evolution to becoming a fully
integrated biopharma company as it prepares for its first expected
drug approval and commercial launch in 2025.
Ms. Wyman brings more than 20 years of leadership and functional
experience in technical and quality operations, including executive
team responsibilities in her most recent roles at
Generate:Biomedicines and Acceleron Pharma. She joins Scholar
Rock’s Executive Team, reporting directly to Jay Backstrom, M.D.,
MPH, President and Chief Executive Officer.
As the Company transitions to a new organizational structure,
the role of Chief Operating Officer (COO) is being eliminated, and
the Company has initiated a search for a Chief Financial Officer
(CFO). Ted Myles, COO & CFO at Scholar Rock, will remain with
the Company through mid-March, and then serve as a Senior Advisor
for six months, during the leadership transition.
“I am delighted to have Lisa join Scholar Rock and further
fortify our readiness to bring apitegromab to the market for
patients and continue to expand our technical and quality
operations for our earlier stage clinical pipeline,” said Dr.
Backstrom. “We are at a critical and exciting stage in our
evolution from a historically R&D focused company, to planning
for our first anticipated commercial product launch. Lisa’s
leadership and technical expertise are instrumental for us to
achieve our mission to discover, develop, and deliver therapies to
improve people’s lives and make a meaningful difference for people
living with serious diseases.”
Dr. Backstrom added, “I am grateful to Ted for his many
contributions to Scholar Rock during a very important period of
organizational growth and transformation and helping us on our path
to becoming a fully integrated biopharma company. On behalf of the
Board of Directors and the entire Executive Team, I would like to
thank Ted for his strong leadership and his continued support
through this transition period. We wish him continued success in
his next industry leadership role.”
Ms. Wyman joins Scholar Rock from Generate:Biomedicines where
she served as Chief Technical Operations Officer, and a member of
the Company’s Executive Leadership Team. While at Generate, she was
responsible for establishing and building out the global technical
operations organization to support its pursuit of developing a
broad portfolio of medicines for patients. Her role included
leading multi-faceted teams across Chemistry, Manufacturing, and
Controls (CMC), technical development, quality, supply
operations.
Prior to Generate, Ms. Wyman served as the Senior Vice President
of Technical Operations and Quality, and member of the Executive
Committee at Acceleron, where she helped to transform the
enterprise from a research and development-focused company to a
fully integrated biotech, which led to the eventual sale of the
company to Merck & Co. in 2021 for over $11 billion. At
Acceleron, she led the CMC strategy for the accelerated development
of sotatercept (marketed as WINREVAIR) for pulmonary arterial
hypertension and supported the launch of Acceleron’s first
commercial product Reblozyl.
Before joining Acceleron, she had roles of increasing
responsibility at Mersana Therapeutics, Shire, and Boston
Scientific. She graduated from Ithaca College with a degree in
biology and earned a master’s degree in engineering management from
Tufts University.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers,
develops, and delivers life-changing therapies for people with
serious diseases that have high unmet need. As a global leader in
the biology of the transforming growth factor beta (TGFβ)
superfamily and named for the visual resemblance of a scholar rock
to protein structures, the clinical-stage company is focused on
advancing innovative treatments where protein growth factors are
fundamental. Over the past decade, Scholar Rock has created a
pipeline with the potential to advance the standard of care for
neuromuscular disease, cardiometabolic disorders, cancer, and other
conditions where growth factor-targeted drugs can play a
transformational role.
This commitment to unlocking fundamentally different therapeutic
approaches is powered by broad application of a proprietary
platform, which has developed novel monoclonal antibodies to
modulate protein growth factors with extraordinary selectivity. By
harnessing cutting-edge science in disease spaces that are
historically under-addressed through traditional therapies, Scholar
Rock works every day to create new possibilities for patients.
Learn more about our approach at ScholarRock.com and follow
@ScholarRock and on LinkedIn.
The efficacy and safety of apitegromab has not been established
and apitegromab has not been approved for any use by the FDA or any
other regulatory agency.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our
investors and the public using our company website
www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on Twitter and
LinkedIn. The information that we post on our website or on Twitter
or LinkedIn could be deemed to be material information. As a
result, we encourage investors, the media and others interested to
review the information that we post there on a regular basis. The
contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without
limitation, Scholar Rock’s expectations regarding its progress and
plans for apitegromab and the ability of any individual to affect
the performance of the Company. The use of words such as “may,”
“could,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify such forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. All such forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, without limitation, that preclinical and
clinical data, including the results from the Phase 3 trial of
apitegromab, are not predictive of, may be inconsistent with, or
more favorable than, data generated from future or ongoing clinical
trials of the same product candidate; Scholar Rock’s ability to
provide the financial support, resources and expertise necessary to
identify and develop product candidates on the expected timeline;
the data generated from Scholar Rock’s nonclinical and preclinical
studies and clinical trials; information provided or decisions made
by regulatory authorities; competition from third parties that are
developing products for similar uses; Scholar Rock’s ability to
obtain, maintain and protect its intellectual property; the success
of Scholar Rock’s current and potential future collaborations;
Scholar Rock’s dependence on third parties for development and
manufacture of product candidates including, without limitation, to
supply any clinical trials; Scholar Rock’s ability to manage
expenses and to obtain additional funding when needed to support
its business activities; its ability to establish or maintain
strategic business alliances; its ability to receive priority or
expedited regulatory review or to obtain regulatory approval of
apitegromab; its ability to expand globally and the anticipated
commercial launch in the United States of apitegromab in the fourth
quarter of 2025; as well as those risks more fully discussed in the
section entitled "Risk Factors" in Scholar Rock’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2024, as well as
discussions of potential risks, uncertainties, and other important
factors in Scholar Rock’s subsequent filings with the Securities
and Exchange Commission. Any forward-looking statements represent
Scholar Rock’s views only as of today and should not be relied upon
as representing its views as of any subsequent date. All
information in this press release is as of the date of the release,
and Scholar Rock undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250129019876/en/
Scholar Rock: Investors Rushmie Nofsinger Scholar
Rock rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Molly MacLeod Scholar Rock mmacleod@scholarrock.com
media@scholarrock.com 802-579-5995
Scholar Rock (NASDAQ:SRRK)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Scholar Rock (NASDAQ:SRRK)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
